Clinical Trials Browser

Unknown × Hodgkin Disease × Alemtuzumab × Clear all

NCT00907036 2013-08-02

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease, Lymphoma

NCT00908180 2013-08-02

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease, Lymphoma